INTRODUCTION
Anti-ribosomal P (anti-P) antibody is one of the autoantibodies found in patients with systemic lupus erythematosus (SLE) [1] [2] [3] . The presence of anti-P antibody is reportedly associated with neuropsychiatric disorders in SLE patients 4 -8 ) . Recent findings indicate that the presence of anti-P antibody is also related to renal damage 9 -l2 ) and vascular thrombosis1 3 ) in SLE patients. We investigated the correlation of anti-P antibody and anti-DNA antibody on lupus nephritis, and investigated the correlation of anti-P antibody and anti-f32 glycoprotein I (anti-f32GPI) antibody or lupus anticoagulant on anti phospholipid syndrome (APS), especially vascular thrombosis, in SLE patients. In addition, the levels of anti-P antibody were compared with titers of anti-DNA antibody and anti-,82GPI antibody or lupus anticoagulant, and were also compared with the results of laboratory tests.
PATIENTS AND METHOD

Patients and sera
Ninety-two patients with SLE attending or admitted to the Rheumatology or Nephrology Division of Ohta Nishinouchi Hospital were enrolled in the present study. Diagnosis of SLE was based on the American College of Rheumatology (ACR) revised criteria for SLE14). As disease controls, 36 patients were enrolled: 12 with rheumatoid arthritis (RA), 4 with systemic sclerosis (SSc), 7 with polymyositis/ dermatomyositis (PM/DM), and 13 with various kinds of vasculitis. Diagnosis of RA, SSc and PM/DM was based on the respective ACR classification criteria. As normal controls, healthy staff members were enrolled. Sera were obtained from clotted blood and stored at -20·C until used.
Clinical features of SLE patients
Clinical features of the 92 SLE patients were classified, based on the major symptoms, into the following 4 groups: lupus nephritis (LN), neuropsychiatric SLE (NPL), APS and "other symptoms". The numbers of patients with these major symptoms (in combination or single symptoms) are shown in Table 1 . A total of 51 patients suffered from LN ; in 40 of those patients, LN was confirmed histologically by renal biopsy. Twenty-one patients suffered from NPL (psychosis, epilepsy, meningitis, or cerebral nerve involvement). Twenty-six patients suffered from APS: 4 patients associated with spontaneous abortion; 10 patients with venous thrombosis, mostly of the deep veins in the legs; and 12 patients with arterial thrombosis in various organs including brain, lung and kidney. Fifteen patients 
Autoantibodies
Anti-ribosomal P (anti-P) antibody was measured using the Ribosomal P ELISA kit (Medical and Biological Laboratory, Nagoya, Japan). Briefly, 100,u1 of 1 : 100-diluted serum was added to each well of a 96-well micro-plate. The wells were coated with the 22 C-terminal amino acids of recombinant ribosomal PO protein. The plates were incubated for 1 hour at room temperature. After washing 4 times with phosphate-buffered saline (PBS; pH 7.4), 100,u1 of peroxidaselabeled goat polyclonal antibody against human immunoglobulins was added. After washing 4 times with PBS, 100,u1 of tetramethylbentidine and H20 2 substrate solution was added to each well, and the optical density (OD) at 450 nm was measured using a spectrophotometer (Bio-Rad, Hercules, CA, USA). The level (index) of anti-P antibody was determined using the following formula: index=(OD intensity of sample-OD intensity of negative control/OD intensity of positive control-OD intensity of negative control) x 100. Antinuclear antibody (ANA) was measured using an immunofluorescence test at the Laboratory Unit of Ohta Nishinouchi Hospital. Anti-double stranded DNA (anti-DNA) and anti-p2GPI antibodies were measured using a standard enzyme-linked immunosorbent assay (ELISA) at the Laboratory Unit of Ohta Nishinouchi Hospital. Lupus anti-coagulant was measured using the silica clotting time method at Mitsubishi Kagaku Bio-Chemical Laboratory, Inc (Tokyo, Japan).
Laboratory testing of blood samples
Peripheral blood cell counts and complement levels (CH50) were measured using routine methods at the Laboratory Unit of Ohta Nishinouchi Hospital.
Statistical analysis
Statistical analysis was performed using the J -STAT software package for Windows. Differences between two groups were evaluated using the chi square test. Correlation between two values was assessed using Spearman's rank correlation coefficient test. P values less than 0.05 were considered to indicate significance. 1 . TAKEDA et at.
RESULTS
Anti-ribosomal P antibody in sera of patients with SLE and various connective tissue-vascular diseases
Serum levels of anti-P antibody (mean±SD) were as follows: SLE sera, 23.5± 35.1 indices; SSc/PM/DM patients, 18.4±15.3 indices; vasculitis patients, 21.5± 18.4 indices; healthy subjects, 3.54±2.27 indices. Levels of anti-P antibody greater than 10.35 indices (mean±3SD) were considered positive for anti-P antibody. The frequencies of positivity for anti-P antibody were as follows: SLE, 43.5% (40/92) ; RA, 0% (0/12); SSc/PM/DM, 9.1% (1/11); vasculitis patients, 30.8% (4/13) (data not shown). Table 2 ). There were 3 SLE patients who were negative for antinuclear antibody but positive for anti-P antibody; they exhibited elevated levels of anti-P antibody (41.3±17.8 index). Two of those 3 patients suffered from nephritis; 1 of these 2 patients also suffered from APS, and the other suffered from NPL syndrome only.
Levels and frequency of anti-ribosomal P antibody in subgroups of SLE patients
Association of the presence of anti-P antibody and anti-DNA antibody with lupus nephritis
The 92 SLE patients were divided into 4 groups depending on presence or absence of anti-DNA antibody and anti-P antibody: group I, positive for both anti-DNA antibody and anti-P antibody; group 2, positive for anti-DNA antibody and negative for anti-P antibody; group 3, negative for anti-DNA antibody and positive for anti-P antibody; group 4, negative for both anti-DNA and anti-P antibody. Numbers of patients and frequency of positivity for lupus nephritis in these 4 groups 
Association of the presence of anti-P antibody and anti-j32GPI antibody and/or lupus anticoagulant with antiphospholipid syndrome
The 92 SLE patients were divided into 4 groups depending on presence or absence of anti-P antibody and anti-j32GPI antibody and/or lupus anticoagulant: group 1, positive for either anti-j32GPI antibody or lupus anticoagulant and positive for anti-P antibody; group 2, positive for either anti-j32GPI antibody or lupus anticoagulant and negative for anti-P antibody; group 3, negative for both antij32GP1 antibody and lupus anticoagulant and positive for anti-P antibody; group 4, negative for both anti-j32GPI antibody and lupus anticoagulant and negative for anti-P antibody. Numbers of patients and frequency of positivity for APS in these anti-DNA, anti-double stranded DNA antibody; anti-P, antiribosomal P antibody; " p < 0.05; ns, not significant 
Correlation between levels of anti-P antibody and results of other laboratory tests
The levels of anti-P antibody were compared with titers of anti-DNA antibody, anti-,82GPI antibody and LAC, levels of serum complement, and counts of red blood cells, white blood cells, lymphocytes and platelets. In the 40 anti-P-positive SLE patients, the level of anti-P antibody correlated inversely with the lymphocyte count (r = -0.661, P < 0.0001) (Figure 1 ). There was no significant correlation between the levels of anti-P antibody and results of other laboratory tests (data not shown).
DISCUSSION
Reported frequencies of anti-P antibody in SLE patients range from 5 to 42%1-3,6). In the present study, anti-P antibody was found in 44% of SLE patients. This high frequency may be due to the sensitivity of the present ELISA kit and the active phase of the present patients. The present finding of a higher prevalence of anti-P antibody in patients with NPL and lupus nephritis is similar to previous findings 2 -6 ,lO,ll). The present finding that the presence of both anti-P antibody and anti-DNA antibody in SLE patients is associated with increased frequency of nephritis is consistent with a report by Reichlin et al. ll ) , who demonstrated that anti-P and anti-dsDNA antibody were strongly associated with nephritis in juveniIe-onset SLE. The exact mechanism of the effect of anti-P antibody on nephritis is unclear. Sun et al. observed a cross reaction of anti-dsDNA antibody with ribosomal P protein on glomerular mesangial cells 1S ), which may explain the exacerbation of nephritis by anti-P antibody. It is also interesting that the presence of both anti-P antibody and anti-,82GPI antibody and/or LAC was associated with increased frequency of anti phospholipid syndrome, especially vascular thrombosis, in the present SLE patients. Yoshio et aUG) reported that anti-P antibody exhibited anti-endothelial cell activity, which may explain the thrombus formation observed in vessels in the present SLE patients. The present finding that levels of anti-P antibody correlated inversely with numbers of lymphocytes suggests that anti-P antibody has anti-lymphocyte activity. This is consistent with findings of Stafford et a1.l7), who observed expression of ribosomal P protein on the cell surface of lymphocytes in both healthy volunteers and SLE patients.
There has been a few paper published which described a correlation between liver damage in SLE patients and anti-P antibody18,19). However, we did not find a significant correlation between liver dysfunction in SLE patients and anti-P antibody in the present study.
In conclusion, the present results indicate that in SLE patients, presence of anti-P antibody and anti-DNA antibody is associated with increased frequency of lupus nephritis, and presence of anti-P antibody and anti-,82GPI antibody and/or LAC is associated with increased frequency of vascular thrombosis. The levels of anti-P antibody in SLE patients correlated inversely with peripheral lymphocyte counts.
